Akira Sawaki

15.9k total citations · 4 hit papers
150 papers, 11.8k citations indexed

About

Akira Sawaki is a scholar working on Pulmonary and Respiratory Medicine, Surgery and Oncology. According to data from OpenAlex, Akira Sawaki has authored 150 papers receiving a total of 11.8k indexed citations (citations by other indexed papers that have themselves been cited), including 88 papers in Pulmonary and Respiratory Medicine, 77 papers in Surgery and 77 papers in Oncology. Recurrent topics in Akira Sawaki's work include Gastric Cancer Management and Outcomes (63 papers), Gastrointestinal Tumor Research and Treatment (42 papers) and Pancreatic and Hepatic Oncology Research (40 papers). Akira Sawaki is often cited by papers focused on Gastric Cancer Management and Outcomes (63 papers), Gastrointestinal Tumor Research and Treatment (42 papers) and Pancreatic and Hepatic Oncology Research (40 papers). Akira Sawaki collaborates with scholars based in Japan, India and United States. Akira Sawaki's co-authors include Atsushi Ohtsu, Yoon‐Koo Kang, Eric Van Cutsem, Florian Lordick, Hyun Cheol Chung, Yung‐Jue Bang, Michaela Lehle, Julie Hill, A. Feyereislova and Lin Shen and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and Gastroenterology.

In The Last Decade

Akira Sawaki

145 papers receiving 11.6k citations

Hit Papers

Trastuzumab in combinatio... 2009 2026 2014 2020 2010 2011 2013 2009 1000 2.0k 3.0k 4.0k 5.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
    2010 5.3k citations Yung‐Jue Bang, Eric Van Cutsem et al. The Lancet profile →
  2. Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
    2011 845 citations Atsushi Ohtsu, Eric Van Cutsem et al. profile →
  3. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
    2013 621 citations Florian Lordick, Yoon‐Koo Kang et al. profile →
  4. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study
    2009 472 citations Narikazu Boku, Toshihiko Doi et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Akira Sawaki 7.4k 6.3k 4.7k 3.0k 1.9k 150 11.8k
Toshihiko Doi 6.4k 0.9× 9.3k 1.5× 3.6k 0.8× 1.8k 0.6× 2.6k 1.3× 424 14.4k
Kyoung‐Mee Kim 4.0k 0.5× 3.4k 0.5× 2.4k 0.5× 1.9k 0.6× 2.0k 1.1× 313 8.3k
Min‐Hee Ryu 4.5k 0.6× 3.7k 0.6× 2.4k 0.5× 2.2k 0.7× 847 0.4× 327 7.6k
Kohei Shitara 6.9k 0.9× 9.3k 1.5× 3.3k 0.7× 2.0k 0.7× 2.2k 1.2× 504 14.2k
Franco Roviello 4.8k 0.7× 2.1k 0.3× 3.9k 0.8× 1.9k 0.6× 1.4k 0.7× 289 8.3k
Yasushi Omuro 4.0k 0.5× 4.0k 0.6× 1.8k 0.4× 1.3k 0.4× 1.3k 0.7× 56 6.7k
Jayesh Desai 4.9k 0.7× 7.7k 1.2× 2.0k 0.4× 2.0k 0.7× 3.5k 1.8× 325 13.4k
Ho Yeong Lim 5.7k 0.8× 6.6k 1.0× 3.6k 0.8× 1.2k 0.4× 3.5k 1.8× 369 15.0k
Maria Dêbiec‐Rychter 7.5k 1.0× 2.7k 0.4× 2.5k 0.5× 4.2k 1.4× 2.4k 1.2× 318 12.3k
Keun‐Wook Lee 3.3k 0.4× 4.0k 0.6× 2.0k 0.4× 1.0k 0.3× 1.3k 0.7× 265 7.3k

Countries citing papers authored by Akira Sawaki

Since Specialization
Citations

This map shows the geographic impact of Akira Sawaki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Akira Sawaki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Akira Sawaki more than expected).

Fields of papers citing papers by Akira Sawaki

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Akira Sawaki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Akira Sawaki. The network helps show where Akira Sawaki may publish in the future.

Co-authorship network of co-authors of Akira Sawaki

This figure shows the co-authorship network connecting the top 25 collaborators of Akira Sawaki. A scholar is included among the top collaborators of Akira Sawaki based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Akira Sawaki. Akira Sawaki is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Sawaki, Akira, Yukinori Kurokawa, Yoshitaka Honma, et al.. (2022). PS4-3 A phase III trial of pimitespib (TAS-116) in patients with advanced gastrointestinal stromal tumor: CHAPTER-GIST-301. Annals of Oncology. 33. S467–S467. 3 indexed citations
3.
Kuzuya, Teiji, Naoto Kawabe, Senju Hashimoto, et al.. (2021). Early Changes in Alpha-Fetoprotein Are a Useful Predictor of Efficacy of Atezolizumab plus Bevacizumab Treatment in Patients with Advanced Hepatocellular Carcinoma. Oncology. 100(1). 12–21. 24 indexed citations
4.
Matsuoka, Hiroshi, Takahiro Hayashi, Kazuyoshi Imaizumi, et al.. (2020). Correlation between immune-related adverse events and prognosis in patients with various cancers treated with anti PD-1 antibody. BMC Cancer. 20(1). 656–656. 55 indexed citations
5.
Kurokawa, Yukinori, Akira Sawaki, Yoshito Komatsu, et al.. (2017). Phase II study of TAS-116, an oral inhibitor of heat shock protein 90 (HSP90), in metastatic or unresectable gastrointestinal stromal tumor refractory to imatinib, sunitinib and regorafenib. Annals of Oncology. 28. v322–v323. 3 indexed citations
6.
7.
Koo, Dong‐Hoe, Min‐Hee Ryu, Kyoung‐Mee Kim, et al.. (2016). Asian Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Stromal Tumor. Cancer Research and Treatment. 48(4). 1155–1166. 145 indexed citations
8.
Igarashi, H, Takuji Okusaka, Tetsuhide Ito, et al.. (2013). Phase II Study of Sunitinib (SU) in Japanese Patients with Well-Differentiated Pancreatic Neuroendocrine Tumor (NET). Annals of Oncology. 24. ix82–ix82. 2 indexed citations
9.
Ogura, Takeshi, Kenji Yamao, Akira Sawaki, et al.. (2012). Take-home Message. Gastrointestinal Endoscopy. 4(75). 769–774. 35 indexed citations
10.
Yamaguchi, Kensei, Akira Sawaki, Toshihiko Doi, et al.. (2012). Efficacy and safety of capecitabine plus cisplatin in Japanese patients with advanced or metastatic gastric cancer: subset analyses of the AVAGAST study and the ToGA study. Gastric Cancer. 16(2). 175–182. 20 indexed citations
11.
Nakao, Makoto, Keitaro Matsuo, Hidemi Ito, et al.. (2011). ABO Genotype and the Risk of Gastric Cancer, Atrophic Gastritis, and Helicobacter pylori Infection. Cancer Epidemiology Biomarkers & Prevention. 20(8). 1665–1672. 54 indexed citations
12.
13.
An, Byonggu, Yasuyuki Okamoto, Keiko Shinjo, et al.. (2011). Distinct Profiles of Epigenetic Evolution between Colorectal Cancers with and without Metastasis. American Journal Of Pathology. 178(4). 1835–1846. 36 indexed citations
14.
Ennishi, Daisuke, Kohei Shitara, Hidemi Ito, et al.. (2011). Association between insulin‐like growth factor‐1 polymorphisms and stomach cancer risk in a Japanese population. Cancer Science. 102(12). 2231–2235. 19 indexed citations
15.
Shitara, Kohei, Kei Muro, Seiji Ito, et al.. (2010). Folate Intake along with Genetic Polymorphisms in Methylenetetrahydrofolate Reductase and Thymidylate Synthase in Patients with Advanced Gastric Cancer. Cancer Epidemiology Biomarkers & Prevention. 19(5). 1311–1319. 31 indexed citations
16.
Bang, Yung‐Jue, Eric Van Cutsem, A. Feyereislova, et al.. (2010). Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. The Lancet. 376(9742). 687–697. 5261 indexed citations breakdown →
17.
Shitara, Kohei, Keitaro Matsuo, Daisuke Takahari, et al.. (2010). Neutropenia as a prognostic factor in advanced gastric cancer patients undergoing second-line chemotherapy with weekly paclitaxel. Annals of Oncology. 21(12). 2403–2409. 50 indexed citations
18.
Kanda, Junya, Keitaro Matsuo, Takeshi Suzuki, et al.. (2008). Impact of alcohol consumption with polymorphisms in alcohol‐metabolizing enzymes on pancreatic cancer risk in Japanese. Cancer Science. 100(2). 296–302. 42 indexed citations
19.
Ueno, Hideki, Tosiya Sato, Seiichiro Yamamoto, et al.. (2006). Randomized, double‐blind, placebo‐controlled trial of bovine lactoferrin in patients with chronic hepatitis C. Cancer Science. 97(10). 1105–1110. 28 indexed citations
20.
Mochizuki, Yoshinari, Yasuhiro Kodera, Michitaka Fujiwara, et al.. (2006). Laparoscopic Wedge Resection for Gastrointestinal Stromal Tumors of the Stomach: Initial Experience. Surgery Today. 36(4). 341–347. 55 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Toshihiko Doi Breakdown of academic impact, for papers by Kyoung‐Mee Kim Breakdown of academic impact, for papers by Min‐Hee Ryu Breakdown of academic impact, for papers by Kohei Shitara Breakdown of academic impact, for papers by Franco Roviello Breakdown of academic impact, for papers by Yasushi Omuro Breakdown of academic impact, for papers by Jayesh Desai Breakdown of academic impact, for papers by Ho Yeong Lim Breakdown of academic impact, for papers by Maria Dêbiec‐Rychter Breakdown of academic impact, for papers by Keun‐Wook Lee
Rankless by CCL
2026